Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The glucagon-like peptide-2 (GLP-2) analogue teduglutide is a medical treatment option for patients with short-bowel syndrome-associated chronic intestinal failure. Because studies in mice have shown that GLP-2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small-intestinal neoplasms has not been reported so far, except for a recent report about de novo development of hamartomatous duodenal polyps. We report a case of de novo development of small-intestinal premalignant adenomatous polyps in both bulbar duodenum and distal jejunum in a patient treated with teduglutide for 41 months. Therefore, additional endoscopic surveillance of the upper gastrointestinal tract may be advised during teduglutide therapy for early detection and removal of potential small-bowel adenomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jpen.1982 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coronary Plaque Volume in an Asymptomatic Population: Miami Heart Study at Baptist Health South Florida.
JACC Cardiovasc Imaging
September 2025
Division of Cardiovascular Prevention and Wellness, Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA.
Background: Coronary computed tomography angiography (CTA)-derived plaque burden is associated with the risk of cardiovascular events and is expected to be used in clinical practice. Understanding the normative values of computed tomography-based quantitative plaque volume in the general population is clinically important for determining patient management.
Objectives: This study aimed to investigate the distribution of plaque volume in the general population and to develop nomograms using MiHEART (Miami Heart Study) at Baptist Health South Florida, a large community-based cohort study.
Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation.
Pediatr Blood Cancer
September 2025
Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Background: The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft-versus-host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft-versus-host disease (cGvHD), potentially allowing pre-emptive adjustment of immunosuppressive treatment.
Procedure: We measured ST2 levels in 117 children undergoing standard hematopoietic stem cell transplantation (HSCT) before conditioning and at regular intervals post-HSCT.
Results: ST2 levels were significantly increased from Day +7 in patients developing aGvHD of any grade (no GvHD: 23.
Heterozygous Med13l mice recapitulate a developmental growth delay and craniofacial anomalies seen in MED13L syndrome.
Dev Dyn
September 2025
Department of Internal Medicine, Division of Cardiovascular Medicine, Francois M. Abboud Cardiovascular Research Center, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, Iowa, USA.
Background: Gene transcription is crucial for embryo and postnatal development and is regulated by the Mediator complex. Mediator is comprised of four submodules, including the kinase submodule (CKM). The CKM consists of MED13, MED12, CDK8, and CCNC.
View Article and Find Full Text PDFBetter growth outcomes in GH-deficient children treated younger than 2 years of age.
Endocr Connect
September 2025
Department of Paediatric Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Background: Limited data are available on the growth response to growth hormone (GH) treatment of very young children with GH deficiency (GHD). In the present analysis, we compared clinical outcomes after GH treatment in children with GHD aged <2 and ≥2 years at the start of GH treatment.
Methods: We analysed pooled data from two observational studies of paediatric patients who received Norditropin® treatment: NordiNet® IOS (NCT00960128) and the ANSWER Program (NCT01009905).
Inhibitor development and clinical characteristics in children with severe hemophilia A in the ATHN 8 US cohort study.
Blood Vessel Thromb Hemost
August 2025
Divsion of Hematology, Oncology & Bone Marrow Transplantation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO.
Clotting factor concentrate (CFC), used to treat and prevent bleeding in hemophilia, is rendered ineffective if clotting factor neutralizing antibodies (inhibitors) develop. Inhibitors occur most often in children, early in treatment. The American Thrombosis and Hemostasis Network (ATHN) 8: US Cohort Study of Previously Untreated Patients (PUPs) with Congenital Hemophilia, conducted in children born in 2010 to 2020 with severe or moderate hemophilia, was designed to determine the percentage of participants who developed a confirmed, clinically significant inhibitor within the first 50 CFC exposure days (EDs).
View Article and Find Full Text PDF